Malaysian Biotechs To Collaborate On Tropical Diseases
This article was originally published in PharmAsia News
Two Malaysian biotech companies in a research partnership plan to place a priority on developing drug-delivery systems for tropical diseases and diagnostics. Biotechnology Corp. and Nanobiotix, which specializes in nanomedicine for cancer therapies, are collaborating on the project. The diagnostics work is focused on developing point-of-care gear for detecting malaria and other tropical diseases. The partnership also gives BiotechCorp global exclusivity for Nanobiotix's platform for non-cancer purposes. (Click here for more
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.